PubMed Health⌕ Search

PubMed · 9884

[Corticoids and shock].

Abstract

After recalling the major role of catecholamines in the genesis of irreversible shock, the anti-shock action of glucocorticosteroids, owing to properties which are "alpha-blocking" , is discussed in this work. The works of LILLEHEI on the effectiveness of corticosteroids in different types of shock are summarized and discussed, as well as numerous works which have followed and a synopsis of which, done in 1967 in the "Annales de l'Anesthésiologie Francaise", is presented. Since then, following new experimental facts, whereas numerous contradictions have appeared in the clinical and experimental realms, the possible mechanisms of action of corticosteroids in shock are looked at, by emphasizing the relationships between corticosteroids and SHWARTZMAN's phenomenon, in particular. A hypothesis on a probable central action of glucocorticosteroids is proposed following experimental works carried out by H. LABORIT et Coll. (1975). Finally, the author presents a personal experiment in hemorrhagic shock in the rabbit where the adjunction of corticosteroids had no effect on the different parameters such as the decrease in PaCO2, hyperlactacidemia and the liberation of beta-glycuronidase in the blood, mortality being practically the same in the controls and in the animals submitted to corticosteroid therapy.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G Laborit. 1976. [Corticoids and shock].. https://pubmed.ncbi.nlm.nih.gov/9884/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗